FDA Approves Vertex Pharmaceuticals’ First-in-Class Non-Opioid Journavx for Moderate-to-Severe Acute Pain
Approval of Journavx for acute pain marks the first new class of acute pain medication approved by the FDA in over 20 years.
Approval of Journavx for acute pain marks the first new class of acute pain medication approved by the FDA in over 20 years.